178748-05-5

Basic information

• Product Name: 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID
• Synonyms: 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID;RARECHEM AL BO 0627;2-(2-fluoro-3-(trifluoromethyl)phenyl)acetic acid;2-fluoro-3-trifluoroethylphenylacetic acid;2-Fluoro-3-(trifluoromethyl)benzoic acid methyl ester;Benzoic acid, 2-fluoro-3-(trifluoroMethyl)-, Methyl ester
• CAS NO: 178748-05-5
• Molecular Formula: C9H6F4O2
• Molecular Weight: 222.14
• EINECS: 200-258-5
• Product Categories: Fluorine series
• Mol File: 178748-05-5.mol

Chemical Properties

• Melting Point: 113-116 °C(lit.)
• Boiling Point: 228℃
• Flash Point: 89℃
• Appearance: /
• Density: 1.345
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID(178748-05-5)
• EPA Substance Registry System: 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID(178748-05-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 178748-05-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Fluoro-3-(Trifluoromethyl)phenylacetic acid is used as a key intermediate in the synthesis of various organic compounds. Its unique structure and strong acidity make it a valuable building block for the creation of complex molecules, which can be further modified or functionalized to achieve desired properties.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 2-Fluoro-3-(Trifluoromethyl)phenylacetic acid is employed as a starting material or intermediate in the production of various drugs. Its presence in the molecular structure can influence the pharmacological properties of the final product, such as potency, selectivity, and bioavailability. 2-FLUORO-3-(TRIFLUOROMETHYL)PHENYLACETIC ACID's stability and reactivity also make it suitable for use in the development of new therapeutic agents.
Used in Research and Development:
2-Fluoro-3-(Trifluoromethyl)phenylacetic acid is utilized in academic and industrial research settings to study the effects of trifluoromethyl substitution on the properties and reactivity of organic compounds. This knowledge can be applied to the design and synthesis of novel molecules with potential applications in various fields, including materials science, agrochemistry, and medicinal chemistry.

Upstream product

• 392-85-8 1-fluoro-2-trifluoromethylbenzene 
• 67-56-1 methanol 
• 115029-22-6 2-fluoro-3-(trifluoromethyl)benzoic acid 

Downstream Products

• 1211596-75-6 methyl 2-cyano-3-(trifluoromethyl)benzoate 

Relevant articles and documents

Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors

We report herein the discovery of quinazolindiones as potent and selective tankyrase inhibitors. Elucidation of the structure-activity relationship of the lead compound 1g led to truncated analogues that have good potency in cells, pharmacokinetic (PK) properties, and excellent selectivity. Compound 21 exhibited excellent potencies in cells and proliferation studies, good selectivity, in vitro activities, and an excellent PK profile. Compound 21 also inhibited H292 xenograft tumor growth in nude mice. The synthesis, biological, pharmacokinetic, in vivo efficacy studies, and safety profiles of compounds are presented.

BISARYL AMIDES AS NRF2 REGULATORS

The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I).

QUINAZOLINEDIONES AS TANKYRASE INHIBITORS

This invention relates to the use of quinazolinediones for the modulation, notably the inhibition of the activity of tankyrases (TNKS1 and TNKS2). Suitably, the present invention relates to the use of quinazolinediones in the treatment of cancer, fibrosis and other hyperproliferative diseases through this mechanism.

Isoxazole derivatives

An isoxazole compound having the following formula: wherein R1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.